Having started my career in basic neuroscience research, I have always understood Alzheimer disease to mean the pathophysiology associated with amyloid plaques and tau tangles. As a clinician, I appreciate that the relationship between Alzheimer disease and cognitive impairment

Thanks for a great conversation today, @axios. Our cause has so much momentum, and new breakthroughs for all are on the horizon. #axioslive

Excited to share our @HarvardAging paper in @NatureMedicine!🧠 More daily steps (even modest levels) were associated w/ slower tau buildup & cognitive decline in preclinical AD, suggesting small changes may have meaningful impact in sedentary older adults! https://t.co/7We7ExIotz

We did it, Texas! Thank you to everyone who supported this campaign. The @alzassociation looks forward to working with state leaders, researchers & community stakeholders to ensure DPRIT delivers on its promise to discover preventions, treatments and one day, cures.

Proud of my colleagues, Nupur Ghoshal and Alexandra Venuto, who worked to make new treatments for Alzheimer's disease more accessible for their patient.

🧠 World Dementia Council reminder: Our next virtual event “Lessons from innovators: biomarkers“ is tomorrow! We'll be discussing vital, collaborative work that is shaping the future of dementia research and care worldwide. Learn more: https://t.co/nXPdBq1keC

🧠 The World Dementia Council is hosting a lunch during @CTADconference. Chaired by @joannepikedrph, we'll explore next-gen therapeutics, biomarkers, diagnostics, and digital health & AI — key themes shaping the future of dementia research. More: https://t.co/T4boM2kQh8

Thanks to the ~3,000 individuals who participated in the 2025 Walk to End Alzheimer's in St. Louis ( https://t.co/brfkjzx4EK), which raised $1.2 million for the Alzheimer's Association. "Whether it’s offering support to anyone facing Alzheimer’s, advocating for the needs and

The @US_FDA's recently approved first blood test for Alzheimer's is poised to be a "game changer", according to DCRI Faculty member Laurie Sanders. See what else she and other experts have to say about the test:

How can #neurologists communicate results of #Alzheimer's #biomarker tests with patients? New episode of our #Neurology in Motion animation series, hosted by Dr. Schindler (@SuzanneESchind1) at @WashUNeurology: https://t.co/jK424VgwaF @alzassociation @AANmember @AmerMedicalAssn

Why should clinicians order blood tests for Alzheimer's disease? 🩸🧠 Clinicians should only order a test if they think it will improve care—how do Alzheimer's disease blood tests improve care? 1️⃣ Blood tests help to answer the important clinical question of whether cognitive

Ten days 'til the gates shut tight Got data, figs, or a tiny light? Seven minutes to make us see Submit now, make your HAI story be! Submit → https://t.co/us9Pa5aZEe #HAI2026 #Neuroimaging

The OBI Scholars Program is recruiting early career scientists of ANY discipline whose research includes mechanistic studies that advance understanding of CNS disease & aging. Scholars receive a generous ~$3M recruitment package and lab space. Learn more: https://t.co/XfBJXBhdVV

🚨New in Lancet Neurology: Autopsy study of aducanumab in #Alzheimer’s shows superficial cortical Aβ cleared, but deeper persists. ARIA showed inflammation+ microinfarcts in leptomeningeal/penetrating vessels. Some path is PET-invisible. @DrNeuroChic https://t.co/gAStfXlsTX...

Congratulations to Eva Klinman, MD, PhD, who was chosen as a 2025 #STATWunderkinds by @STATNews for her work developing a new model for neurodegenerative diseases like #alzheimer and #dementia! @WashUMedicine #WashUMed https://t.co/34QNTwKAGf

The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings specifically to rule out the presence of amyloid, a hallmark of the disease. “This is another important step toward expanding access to Alzheimer’s disease diagnostic tools,” said our

NIH Leadership Is Failing Early Career Researchers Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers. https://t.co/WgDt2fzcWW

Has your research funding been cut by the administration? NYT wants to hear from you. We need to be loud now, not quiet, about these things. The attacks on science have to stop. Spread widely. https://t.co/1lQ6AThHQa

It’s official. 🎉 @EdwardJones has renewed its commitment to raising awareness and critical funds for the fight to #ENDALZ nationwide through 2030! Since 2016, more than 130,000 Edward Jones associates, clients and family members have united to raise over $55 million through

Thank you to @AlzheimerEurope for hosting a plenary at #35AEC about how Europe is preparing for the introduction of disease-modifying treatment. In this new era of treatment & care, we must improve early diagnosis, strengthen health systems & increase equity — together.

With so many clinical trials in progress across the country, it can be difficult for interested research participants to know where to start. @j_graffradford joins #DementiaMatters to discuss the ins and outs of Alzheimer's disease clinical trials and the state of treatments